China
Africa
Explore chapters and articles related to this topic
Atherosclerosis
Published in George Feuer, Felix A. de la Iglesia, Molecular Biochemistry of Human Disease, 2020
George Feuer, Felix A. de la Iglesia
In the antienzyme type of autoimmune hyperlipidemia, the inhibition of lipolysis is due to antibodies that interfere with (1) lipase activation, (2) lipase function, or (3) lipase synthesis. The hypolipoproteinemia may be type I, IV, or V. There is no agglutination, fat tolerance tests are abnormal, and postheparin lipase activity is decreased.
Curcumin and blood lipid levels: an updated systematic review and meta-analysis of randomised clinical trials
Published in Archives of Physiology and Biochemistry, 2022
Farhad Saeedi, Tahereh Farkhondeh, Babak Roshanravan, Alireza Amirabadizadeh, Milad Ashrafizadeh, Saeed Samarghandian
This meta-analysis was carried out under PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. A systematic literature search was done in the several databases including Ovid-Medline, Web of Science, Scopus, Cochrane, Embase, ProQuest between January 2014 and January 2019. Due to increase of sensitivity and specificity, a combination of the following search Medical Subject Headings (MESH) and non-MESH terms has been used to detect studies: “Curcuma” OR “Curcumin” OR “turmeric” OR “curcuminoids” OR “diferuloylmethane” AND “lipid*”, OR “hyperlipidemia*” OR “lipid metabolism disorders” OR “lipid metabolism” OR “Cholesterol” OR “low-density lipoprotein” OR “hyperlipidaemia “OR “hypercholesterolemia” OR “hypocholesterolemia” OR “high-density lipoprotein” OR “triglycerides” OR “hypertriglyceridemia*” OR “hypotriglyceridemia” OR “very-low-density lipoproteins” OR “dyslipidemia” OR “low-density lipoprotein” OR “hypolipoproteinemia” and “randomized controlled trial” OR “randomised controlled trials were selected as keywords.
Gene-based therapy in lipid management: the winding road from promise to practice
Published in Expert Opinion on Investigational Drugs, 2020
Tycho R. Tromp, Erik S.G. Stroes, G. Kees Hovingh
Multiple studies have shown that rare LOF variants in ANGPTL3 are associated with decreased plasma levels of triglycerides, LDL-C, HDL-C and with decreased risk for coronary heart disease [65,66]. These findings were preceded by the discovery of combined hypolipidaemia phenotypes (i.e. low LDL-C, low HDL-C, and low triglyceride levels) in ANGPTL3 knock-out mice [67] and later in a family with autosomal dominantly inherited hypolipoproteinemia with LOF variants in ANGPTL3 [68]. Additionally, angptl3 plasma levels have been associated with myocardial infarction in the PROMIS cohort (a matched case–control study of Pakistani patients with myocardial infarction comprising 1493 cases and 3231 matched controls) [66]. Patients in the lowest two tertiles of angptl3 plasma levels had a reduced risk of myocardial infarction compared with the highest tertile with odds ratios of 0.75 (95%-CI: 0.64–0.88) and 0.65 (95%-CI: 0.55–0.77), respectively.